Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial
Authors
Keywords
-
Journal
Lancet Respiratory Medicine
Volume 10, Issue 5, Pages 469-477
Publisher
Elsevier BV
Online
2022-03-25
DOI
10.1016/s2213-2600(21)00556-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The different phenotypes of COPD
- (2021) Ahmed Yousuf et al. BRITISH MEDICAL BULLETIN
- Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial
- (2021) Steven G. Kelsen et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Association between plasma interleukin-33 level and acute exacerbation of chronic obstructive pulmonary disease
- (2021) Hyonsoo Joo et al. BMC Pulmonary Medicine
- The central role of IL-33/IL-1RL1 pathway in asthma: From pathogenesis to intervention
- (2021) A.K. Saikumar Jayalatha et al. PHARMACOLOGY & THERAPEUTICS
- Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial
- (2021) Klaus F Rabe et al. Lancet Respiratory Medicine
- Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma
- (2020) Michael C Peters et al. LANCET
- Inflammatory Endotype Associated Airway Microbiome in COPD Clinical Stability and Exacerbations – A Multi-Cohort Longitudinal Analysis
- (2020) Zhang Wang et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Airway inflammation in COPD- progress to precision medicine
- (2019) Christopher Brightling et al. EUROPEAN RESPIRATORY JOURNAL
- Benralizumab for the Prevention of COPD Exacerbations
- (2019) Gerard J. Criner et al. NEW ENGLAND JOURNAL OF MEDICINE
- T2 Biologics for Chronic Obstructive Pulmonary Disease
- (2019) Ahmed Yousuf et al. Journal of Allergy and Clinical Immunology-In Practice
- Pulmonary IL‐33 orchestrates innate immune cells to mediate RSV‐evoked airway hyperreactivity and eosinophilia
- (2019) Yi‐Hsiu Wu et al. ALLERGY
- Dichotomous function of IL-33 in health and disease: From biology to clinical implications
- (2018) Harald Braun et al. BIOCHEMICAL PHARMACOLOGY
- Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles
- (2018) Michael A. Ghebre et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease
- (2017) Ian D. Pavord et al. NEW ENGLAND JOURNAL OF MEDICINE
- The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases
- (2017) Brad Griesenauer et al. Frontiers in Immunology
- Cell death and inflammation: the case for IL-1 family cytokines as the canonical DAMPs of the immune system
- (2016) Seamus J. Martin FEBS Journal
- IL-33 Precedes IL-5 in Regulating Eosinophil Commitment and Is Required for Eosinophil Homeostasis
- (2016) Laura K. Johnston et al. JOURNAL OF IMMUNOLOGY
- Increased IL-33 expression in chronic obstructive pulmonary disease
- (2015) Jie Xia et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Cigarette Smoke Silences Innate Lymphoid Cell Function and Facilitates an Exacerbated Type I Interleukin-33-Dependent Response to Infection
- (2015) Jennifer Kearley et al. IMMUNITY
- Functional analysis of protective IL1RL1 variants associated with asthma risk
- (2015) Vladimir Ramirez-Carrozzi et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- IL-13 mediates IL-33–dependent mast cell and type 2 innate lymphoid cell effects on bronchial epithelial cells
- (2015) Deepti R. Nagarkar et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD
- (2015) A.M. Kirsten et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- IL-33–Dependent Type 2 Inflammation during Rhinovirus-induced Asthma ExacerbationsIn Vivo
- (2014) David J. Jackson et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling
- (2014) Jennifer E. Ho et al. JOURNAL OF CLINICAL INVESTIGATION
- Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study
- (2014) Christopher E Brightling et al. Lancet Respiratory Medicine
- TNFα antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial
- (2012) Shawn D Aaron et al. THORAX
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started